LIVE FROM CPhI – Endeavour launches compounds for oncology research

Seventy five original compounds added to catalogue in last 12 months

UK-based Endeavour Speciality Chemicals has launched additions to its range of novel building blocks and reactive intermediates, including new compounds targeted at oncology research and a focused selection for researchers studying nanomaterials.

The new, non-exclusive products will be available from stock in small packs (1g – 100g) for early stage r&d or larger quantities (100g – 100kg) for projects moving through the development stage.

With the introduction of the new products, Endeavour will have added 75 original compounds to its catalogue of more than 900 products since the 2009 CPhI Worldwide event in Madrid. Designed for the synthesis of complex molecules, the majority of Endeavours' products are based on its core technologies of sulphur and heterocyclic chemistry.

‘We are constantly designing and developing innovative products to meet the demands of research and discovery scientists as well as looking at new applications for existing products,’ said Endeavour sales manager Jordi Robinson. ‘The new oncology and nanomaterials offers illustrate the diversity of our capabilities across a wide range of market segments.’

Endeavour's products have applications across several industry sectors, including pharmaceuticals, agrochemicals and materials sciences. Together with parent company, Robinson Brothers, Endeavour can support projects from initial development through to full-scale commercial production.

Robinson Brothers and Endeavour have extensive experience in both sulphur and heterocyclic chemistries and the company is also recognised as a market leader in hydrogenation technology.